Deal Watch: Pfizer Circles Allergan, Which Continues Its Own M&A
Allergan remains active, acquiring EU rights to Ironwood's linaclotide from Spain's Almirall. Novartis adds to its immuno-oncology pipeline with Admune purchase, it third I-O transaction in the past month.
You may also be interested in...
The dealmaking machine has proposed buying Dendreon’s assets, including prostate cancer immunotherapy Provenge, through a bankruptcy rummage sale.
Given mixed Phase III results for the Alzheimer’s drug and potentially severe side effects for the once-monthly infused therapy, ICER’s recommendation came in below analyst expectations.
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.